Abbott Laboratories (ABT) reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, up 17.1% year over year.
THAT’S UPSETTING, SINCE THIS IS THE ONE THE INSTA-WIFE HAS: St. Jude Medical Played Down Defibrilla…
THAT’S UPSETTING, SINCE THIS IS THE ONE THE INSTA-WIFE HAS: St. Jude Medical Played Down Defibrillator Failures for Years, F.D.A. Says.
On Mar 31, we updated our research report on medical device major, Abbott Laboratories (ABT).
MedTech Long-Term Prospects Impress: Which Stocks to Buy?
Abbott Laboratories (ABT) recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S.
Abbott Laboratories (ABT) just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion.
Abbott Laboratories (ABT) reported fourth-quarter 2016 earnings from continuing operations of 65 cents per share, a penny higher than the Zacks Consensus Estimate.
Abbott Laboratories (ABT) earnings per share has beaten the Zacks Consensus Estimated while its revenues were almost in line with the mar.
Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.
21ST CENTURY HEADLINES: St. Jude Medical releases security patches for vulnerable cardiac devices. …
21ST CENTURY HEADLINES: St. Jude Medical releases security patches for vulnerable cardiac devices. “The transmitters record and receive RF traffic from the embedded medical devices before sending this information to physicians through the Merlin.net Patient Care Network. The US agency has investigated a set of security flaws found within this setup by MedSec and has […]
Компания St. Jude Medical все же была вынуждена признать уязвимость своих продуктов после прошлогоднего скандала.
IDEXX Laboratories, Inc. (IDXX) is scheduled to join the coveted S&P 500 benchmark, after the market closes on Jan 4.
Abbott Laboratories (ABT) announced to close the acquisition of St. Jude Medical, Inc., (STJ) on Jan 4, 2017.
Abbott Laboratories (ABT) has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical (STJ).
The Federal Trade Commission’s approval of Abbott Laboratories’ $25 billion purchase of St. Jude Medical helps the larger company cope with value-based care and bundled payments to doctors and hospitals.
Вчера, 27 декабря, антимонопольные органы США одобрили $25-миллиардную сделку по приобретению американской фармацевтической компанией Abbott Laboratories производителя медицинских устройств St. Jude Medical. Напомним, что месяцем ранее сделка была одобрена Европейской комиссией при условии, что Abbott выведет два актива в сфере лечения сердечно-сосудистой системы.